

## I. AMENDMENTS

### In the Claims

Please cancel claims 1, 19, and 20 without prejudice and disclaimer.

Please amend claims 7-10, 12-14 as follows:

7. (Twice Amended) The method according to [any one of claims 1, and] claim 5 wherein the allergen-induced inflammatory disorder features a local immune response characterized by increased production of TNF- $\alpha$ .

8. (Twice Amended) The method according to [any one of claims 1, and] claim 5 wherein the lactoferrin product is a naturally occurring lactoferrin.

9. (Twice Amended) The method according to [any one of claims 1, and] claim 5 wherein the lactoferrin product is a recombinantly produced lactoferrin or a biologically active analog thereof.

10. (Twice Amended) The method according to [any one of claims 1, and] claim 5 wherein the lactoferrin product is a biologically active fragment of lactoferrin.

12. (Twice Amended) The method according to [any one of claims 1, and] claim 5 wherein the inflammatory disorder is a dermal inflammatory disorder.

13. (Twice Amended) The method according to [any one of claims 1, and] claim 5 wherein the inflammatory disorder is selected from the group consisting of contact dermatitis, psoriasis, UV-induced inflammation, infant diaper rash, and acne.

14. (Twice Amended) The method according to [any one of claims 1, and] claim 5 wherein the lactoferrin product is administered in a composition further comprising an anti-wrinkle agent and the inflammatory disorder is facial skin aging.

Please add the following new claims:

21. (New) A method of inhibiting in a mammal a dermal inflammatory response that is characterized by accumulation of dendritic cells in lymph nodes, comprising administering to the mammal a pharmaceutically effective amount of lactoferrin product that reduces the accumulation of dendritic cells in the lymph nodes.

22. (New) The method of claim 21, wherein the dermal inflammatory response is induced by an allergen.

23. (New) The method of claim 21, wherein the dermal inflammatory response is mediated by TNF- $\alpha$ .

24. (New) The method of claim 21, wherein the dermal inflammatory response is further characterized by Langerhans cell migration.

25. (New) The method of claim 21, wherein the dermal inflammatory response is manifested as a disorder selected from the group consisting of contact dermatitis, psoriasis, UV-induced inflammation, skin aging, infant diaper rash, and acne.

## II. REMARKS

### Status of Claims

Claims 1, 5-10, 12-14, and 20 have been examined and are rejected on various grounds.